Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 7017-7024

  Song, Yin Dong ^a   Zhang, Ke Fei ^a   Liu, Dong ^a   Guo, Yan Qi ^b   Wang, Da Yong ^a   Cui, Ming Yu ^a   Li, Gang ^a   Sun, Yuan Xin ^a   Shen, Jian Hui ^a   Li, Xin Gang ^a   Zhang, Long ^a   Shi, Feng Jun ^a  

^a DAQING OILFIELD CO LTD   (China)

^b Oil Recovery Plant No 1 Daqing Oilfied Corp   (China)

Author keywords

Chondrosarcomas; EGFR; Glucose metabolism

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE; GLUCOSE TRANSPORTER 1; LACTATE DEHYDROGENASE; PLASMID DNA; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY ASSAY; CHONDROSARCOMA; CONTROLLED STUDY; CULTURE MEDIUM; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; WESTERN BLOTTING;

CELL LINE, TUMOR; CHONDROSARCOMA; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HUMANS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84905015568     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1902-4     Document Type: Article

References (26)

1. Bertoni F, Bacchini P, Hogendoorn PCW. Chondrosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002. p. 247-51.
2. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008;13:320-9. (Pubitemid 351679908)
3. Fiorenza F, Abudu A, Grimer RJ, Carter SR, Tillman RM, Ayoub K, et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg (Br). 2002;84:93-9. (Pubitemid 34105631)
4. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci U S A. 2002;99:4592-5. (Pubitemid 34286029)
5. Helm CW, States JC. Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. J Ovarian Res. 2009;2:2.
6. Homma A, Inamura N, Oridate N, Suzuki S, Hatakeyama H, Mizumachi T, et al. Concomitant weekly cisplatin and radiotherapy for head and neck cancer. Jpn J Clin Oncol. 2011;41:980-6.
7. Fernandez DMS, Villalonga P, Clardy J, Lam EW. Foxo3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther. 2008;7:3237-46.
8. Konstantakou EG, Voutsinas GE, Karkoulis PK, Aravantinos G, Margaritis LH, Stravopodis DJ. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int J Oncol. 2009;35:401-16.
9. Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, et al. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One. 2013;8:e54193.
10. Fuertes MA, Castilla J, Alonso C, Perez JM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 2003;10:257-66. (Pubitemid 36131658)
11. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869-83.
12. van Oosterwijk JG, Herpers B, Meijer D, Briaire-de BI, Cleton-Jansen AM, Gelderblom H, et al. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: bcl-2 family members cause chemoresistance. Ann Oncol. 2012;23:1617-26.
13. Li H, Zhang X, Song X, Zhu F, Wang Q, Guo C, et al. Pdcd5 promotes cisplatin-induced apoptosis of glioma cells via activating mitochondrial apoptotic pathway. Cancer Biol Ther. 2012;13:822-30.
14. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59:21-6. (Pubitemid 38610223)
15. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, et al. Survival of cancer cells is maintained by egfr independent of its kinase activity. Cancer Cell. 2008;13:385-93. (Pubitemid 351609444)
16. Benhar M, Engelberg D, Levitzki A. Cisplatin-induced activation of the egf receptor. Oncogene. 2002;21:8723-31. (Pubitemid 36132393)
17. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. Oncomine: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6:1-6. (Pubitemid 38391943)
18. Iyer R, Bharthuar A. A review of erlotinib - an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert Opin Pharmacother. 2010;11:311-20.
19. Zhai X, Yang Y, Wan J, Zhu R, Wu Y. Inhibition of LDH-A by oxamate induces G2/M arrest, apoptosis and increases radiosensitivity in nasopharyngeal carcinoma cells. Oncol Rep. 2013;30:2983-91.
20. Zhang YX, van Oosterwijk JG, Sicinska E, Moss S, Remillard SP, van Wezel T, et al. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin Cancer Res. 2013;19:3796-807.
21. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 2-deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007;67:3364-70. (Pubitemid 46724876)
22. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012;11:1672-82.
23. Liang XJ, Finkel T, Shen DW, Yin JJ, Aszalos A, Gottesman MM. Sirt1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res. 2008;6:1499-506.
24. Vander HM, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-33.
25. Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, et al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-a resensitizes taxol-resistant cancer cells to taxol. Mol Cancer. 2010;9:33.
26. Lu CW, Lin SC, Chien CW, Lin SC, Lee CT, Lin BW, et al. Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. Am J Pathol. 2011;179:1405-14.